Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Šimůnek, T., Štěrba, M., Popelová, O., Adamcová, M., Hrdina, R., & Geršl, V. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70018-0 · Cited by 769
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.3879 · Cited by 493
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles
Mayer, L. D., Hope, M. J., Cullis, P. R., & Janoff, A. S. (1985) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(85)90084-7 · Cited by 436
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
ABC proteins : from bacteria to man
Holland, I. B., Cole, S. P. C., Kuchler, K., & Higgins, C. F. (2003) · Medical Entomology and Zoology · Cited by 361
Cited by
Ferroptosis as a target for protection against cardiomyopathy
Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wei, J., Gu, S., Gao, F., Zhu, N., Yin, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821022116 · Cited by 2,127
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Fang, X., Ardehali, H., Min, J., & Wang, F. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00735-4 · Cited by 1,081
Self-citationAnthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111708 · Cited by 909
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity
Tadokoro, T., Ikeda, M., Ide, T., Deguchi, H., Ikeda, S., Okabe, K., Ishikita, A., Matsushima, S., Koumura, T., Yamada, K.-I., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132747 · Cited by 655
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy
Wallace, K. B., Sardão, V. A., & Oliveira, P. J. (2020) · Circulation Research · doi:10.1161/circresaha.119.314681 · Cited by 599
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Oxidative stress injury in doxorubicin-induced cardiotoxicity
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.02.013 · Cited by 566
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 531
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Murphy, E., Ardehali, H., Balaban, R. S., DiLisa, F., Dorn, G. W., Kitsis, R. N., Otsu, K., Ping, P., Rizzuto, R., Sack, M. N., et al. (2016) · Circulation Research · doi:10.1161/res.0000000000000104 · Cited by 458
Self-citationKong, C.-Y., Guo, Z., Song, P., Zhang, X., Yuan, Y.-P., Teng, T., Yan, L., & Tang, Q.-Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65258 · Cited by 412
Mitochondrial iron–sulfur clusters: Structure, function, and an emerging role in vascular biology
Read, A. D., Bentley, R. E., Archer, S. L., & Dunham-Snary, K. J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102164 · Cited by 408
Quagliariello, V., De Laurentiis, M., Rea, D., Barbieri, A., Monti, M. G., Carbone, A., Paccone, A., Altucci, L., Conte, M., Canale, M. L., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01346-y · Cited by 367
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Click and release: bioorthogonal approaches to “on-demand” activation of prodrugs
Ji, X., Pan, Z., Yu, B., De La Cruz, L. K., Zheng, Y., Ke, B., & Wang, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00395e · Cited by 335
Bayır, H., Dixon, S. J., Tyurina, Y. Y., Kellum, J. A., & Kagan, V. E. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00689-x · Cited by 331
Kalyanaraman, B. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101394 · Cited by 326
Wang, Y., Yan, S., Liu, X., Deng, F., Wang, P., Yang, L., Hu, L., Huang, K., & He, J. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00990-5 · Cited by 315
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Meredith, A.-M., & Dass, C. R. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12539 · Cited by 303
Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity
Koleini, N., & Kardami, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16944 · Cited by 301
Hu, C., Zhang, X., Wei, W., Zhang, N., Wu, H., Ma, Z., Li, L., Deng, W., & Tang, Q. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.003 · Cited by 261
Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity
Wu, B. B., Leung, K. T., & Poon, E. N.-Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031912 · Cited by 237
“DOX, doxorubicin; ER, endoplasmic reticulum; TRPC, transient receptor potential canonical; IRP, iron-regulatory protein; TfR, transferrin receptor; DMT1, divalent metal transporter 1; mPTP, mitochondrial permeability transition pore; Δψm, mitochondrial membrane potential; TOP2β, topoisomerase 2β; RYR2, ryanodine recep…”
BackgroundInfluentialShi, S., Chen, Y., Luo, Z., Nie, G., & Dai, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01077-5 · Cited by 233
“DOX treatment brings about the accumulation of Fe2+ within the mitochondria by downregulating ABCB8 expression and reducing Fe2+ expulsion [159].”
BackgroundA review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging
Linders, A. N., Dias, I. B., López Fernández, T., Tocchetti, C. G., Bomer, N., & Van der Meer, P. (2024) · npj Aging · doi:10.1038/s41514-024-00135-7 · Cited by 231
“Doxorubicin accumulates in mitochondria, partially by binding to cardiolipin 111,112 .”
BackgroundArmenian, S. H., Armstrong, G. T., Aune, G., Chow, E. J., Ehrhardt, M. J., Ky, B., Moslehi, J., Mulrooney, D. A., Nathan, P. C., Ryan, T. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.3920 · Cited by 229
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention
Bhagat, A., & Kleinerman, E. S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_15 · Cited by 208
Li, M., Sala, V., De Santis, M. C., Cimino, J., Cappello, P., Pianca, N., Di Bona, A., Margaria, J. P., Martini, M., Lazzarini, E., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030352 · Cited by 207
Mitochondrial Iron in Human Health and Disease
Ward, D. M., & Cloonan, S. M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114742 · Cited by 195
“Finally, the mitochondrial-localized ATP-binding cassette protein ABCB8 has been suggested to play a role in iron export, although these observations have only been reported in conditions of cardiotoxicity (61, 62), and so the normal role of ABCB8 remains to be elucidated.”
BackgroundNew signal transduction paradigms in anthracycline-induced cardiotoxicity
Ghigo, A., Li, M., & Hirsch, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.021 · Cited by 194
de Boer, R. A., Hulot, J.-S., Tocchetti, C. G., Aboumsallem, J. P., Ameri, P., Anker, S. D., Bauersachs, J., Bertero, E., Coats, A. J. S., Čelutkienė, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2029 · Cited by 183
Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Sawicki, K. T., Sala, V., Prever, L., Hirsch, E., Ardehali, H., & Ghigo, A. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030620-104842 · Cited by 177
Self-citationGovender, J., Loos, B., Marais, E., & Engelbrecht, A. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12176 · Cited by 176
“DXR is known to accumulate ferrous iron which in turn induces oxidative damage to CK, disrupting energy homeostasis by decreasing both ATP and PCr levels [55].”
BackgroundGut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities
Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022) · Microorganisms · doi:10.3390/microorganisms10102048 · Cited by 162
Physical Exercise: A Novel Tool to Protect Mitochondrial Health
Sorriento, D., Di Vaia, E., & Iaccarino, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.660068 · Cited by 118
Doxorubicin-induced cardiotoxicity: causative factors and possible interventions
Jones, I. C., & Dass, C. R. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac063 · Cited by 91
Cheng, Q., Du, L., Meng, L., Han, S., Wei, T., Wang, X., Wu, Y., Song, X., Zhou, J., Zheng, S., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11789 · Cited by 85
Nowak-Jary, J., & Machnicka, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212013 · Cited by 74
Smith, M. J., Fowler, M., Naftalin, R. J., & Siow, R. C. M. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.04.024 · Cited by 40
Ghio, A. J., Soukup, J. M., Dailey, L. A., & Madden, M. C. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.007 · Cited by 39
Dynamic Metabolic Response to Adriamycin-Induced Senescence in Breast Cancer Cells
You, R., Dai, J., Zhang, P., Barding, G. A., & Raftery, D. (2018) · Metabolites · doi:10.3390/metabo8040095 · Cited by 24
“Previously, it was shown that iron accumulation in mitochondria occurs as a result of ADR and causes cardiotoxicity [29].”
Background
Metadata
- Authors
- Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Prasad, S. V. N., Mutharasan, R. K., Naik, T. J., & Ardehali, H.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-02
- Volume
- 124
- Issue
- 2
- Pages
- 617-630
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2112885253
- Cited by
- 878
- References
- 50
- FWCI
- 35.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.